Navigation Links
Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
Date:10/23/2007

HAYWARD, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) presented updated data today from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated antitumor activity and tolerability in patients with solid tumors. KOS-1584/R1645 showed signs of activity in patients with non-small cell lung, ovarian, breast, prostate, pancreatic, head and neck and colon cancer. The Phase 1 trial explored two different schedules of KOS-1584/R1645 using escalating doses. Data reported today were from a trial investigating weekly dosing schedules (weekly 2 weeks out of 3 weeks and weekly 3 weeks out of 4 weeks). Common toxicities were generally low-grade and manageable.

Data from the Phase 1 trial of KOS-1584/R1645 were presented in a poster titled, "Optimization of the Phase 2 Dose of KOS-1584 (a Novel, Synthetic Epothilone) via Weekly Administration," by Howard Burris, M.D., Sarah Cannon Research Institute, Nashville, TN, at the 2007 Annual Meeting of the American Association for Cancer Research/National Cancer Institute/European Organization for Research and Treatment of Cancer (AACR/NCI/EORTC).

"We believe that KOS-1584 has the potential to achieve best-in-class status in the emerging epothilone market as well as to compete in the established taxane market," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "We look forward to our planned commencement of a Phase 2 clinical program for KOS-1584 toward the end of 2007."

Phase 1 Trial Results of KOS-1584

The Phase 1 trial was designed to define the maximum tolerated dose, dose-limiting toxicity and recommended Phase 2 dose and to
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
8. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... and TORONTO , Aug. ... (OTCQB: GNBT) today announced the issuance of a white ... proprietary buccal insulin spray product.  The white paper was ... the Company,s stockholders by Dr. James H. Anderson, ... white paper may be viewed online on the Generex ...
(Date:8/27/2015)... Pa. , Aug. 27, 2015  PinnacleHealth CardioVascular Institute ... and second in the United States ... new type of stent for blockages in the main artery ... within the artery and potentially less risk for stent fracture ... is a prospective, single-arm, multicenter clinical trial of the BioMimics ...
(Date:8/27/2015)... , August 27, 2015 ... Persistence Market Research titled "Global Market Study on ... Growth by 2021", the urinary catheters market is expected to ... of 2015. It is anticipated to expand at ... reach US$1,755.0 Mn by 2021. View ...
Breaking Medicine Technology:Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4First Pennsylvania Patient Treated in Landmark Vascular Study 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 2Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 3Global Urinary Catheters Market Will Reach US$1,755.0 Mn by 2021: Persistence Market Research 4
... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... and Chief Executive Officer, will present at the Cowen ... Boston Marriott Copley Place.  The presentation is scheduled for ...
... 2011 HeartWare International, Inc. (Nasdaq: HTWR ... miniaturized circulatory support technologies that are revolutionizing the treatment ... Godshall is scheduled to make an investor presentation at ... a.m. Eastern Time on Tuesday, March 15, 2011. The ...
Cached Medicine Technology:AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference 2HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference 2
(Date:8/27/2015)... ... 2015 , ... According to an article published August 13 by ... many conversations between hernia experts surrounding the search for the ideal hernia mesh. With ... experts have different ideas about which is the best mesh for their patients. What ...
(Date:8/27/2015)... ... 27, 2015 , ... In an article published July 30th by ... of New Orleans, highlighting a security firm that is tasked with providing supplemental protection. ... entrepreneur who worked with the city to provide private security when it is needed ...
(Date:8/27/2015)... PA (PRWEB) , ... August 27, 2015 , ... ... Health Network , is one of just 20 adult-only medical centers in the ... for people with failing hearts and lungs. The Extracorporeal Life Support Organization ...
(Date:8/27/2015)... ... August 27, 2015 , ... On May 30th, 2015, at the Adams County ... of the “Music With A Mission” benefit concert. For the past two years, “Music ... the underfunded school districts of Mendon and neighboring town, Quincy, IL. Organized in part ...
(Date:8/27/2015)... PLAINSBORO, N.J. and WILMINGTON, Del. (PRWEB) , ... August 27, 2015 ... ... at Texas Children’s Hospital, will be the guest speaker at CURE® magazine’s 3rd ... meeting of hematologists. , Dr. Arnold will be among hundreds of attendees honoring eight ...
Breaking Medicine News(10 mins):Health News:Recent Article on Hernia Mesh Developments Highlights Viable Options, But Shows a Need for Further Research, notes Dr. Shirin Towfigh 2Health News:Article on New Orleans Security Force Highlights the Abilities and Flexibility of Private Security, says Spear Security Inc. 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 2Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 3Health News:Dr. Jennifer Arnold of ‘The Little Couple’ to Keynote 3rd Annual MPN Heroes™ Recognition Event in Orlando 4
... offers tips on digestive disorders , , SATURDAY, March 28 (HealthDay ... a one-time bellyache, but it also could be a sign ... Boland, chief of gastroenterology at Baylor University Medical Center in ... digestive disorders: , Symptoms : Alert your ...
... safe and superior to bare metal stents in preventing ... in a nationwide registry of cardiovascular disease, according to ... findings were presented today at the i2Summit at the ... also appear online in the Journal of the ...
... more than $19 billion dollars of funding provided for ... stimulus package offers a unique opportunity to deliver on ... Children,s Hospital Boston in a Perspective article published in ... Journal of Medicine (NEJM). The co-authors argue that ...
... DRx Corporation (Nasdaq: VETS ) a provider of ... announced that the Company will release its financial results for ... to the opening of the market on Wednesday, April 1, ... call on Thursday, April 2, beginning at 2:00 p.m. Eastern ...
... to pay restitution of $2.3 billion and forfeit $1.7 ... Enterprises (NCFE) executives were sentenced today for their roles ... health of NCFE, Acting Assistant Attorney General Rita M. ... Southern District of Ohio announced. NCFE, formerly based in ...
... flu shot, will have Tamiflu available for purchase as well. , ... Van Nuys, CA ... influenza virus that is easily caught upon contact with the virus. The flu ... fatal. The best prevention of the flu is to get the annual ...
Cached Medicine News:Health News:What You Need to Know When Your Stomach Aches 2Health News:Drug-eluting stents found safe, superior to bare metal stents 2Health News:Billions spent on health IT stimulus could lead to major boom... or bust 2Health News:Pet DRx to Hold Its Fourth Quarter and Year-End 2008 Financial Results Conference Call 2Health News:Former National Century Financial Enterprises CEO Sentenced to 30 Years in Prison, Co-owner Sentenced to 25 Years in Prison for Conspiracy, Fraud and Money Laundering 2Health News:Former National Century Financial Enterprises CEO Sentenced to 30 Years in Prison, Co-owner Sentenced to 25 Years in Prison for Conspiracy, Fraud and Money Laundering 3Health News:Former National Century Financial Enterprises CEO Sentenced to 30 Years in Prison, Co-owner Sentenced to 25 Years in Prison for Conspiracy, Fraud and Money Laundering 4Health News:Nationwide Medical/Surgical Announces Availability of Tamiflu for the 2009-2010 Influenza Season 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: